Polyplus-transfection and the National Institute of Health sign a research license agreement
Advertisement
Polyplus-transfection SA announces that it has granted two agencies of the United States National Institutes of Health (“NIH”) a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and infectious diseases (“NIAID”) and the National cancer Institute (“NCI”).
The NIAID and the NCI, by entering into this license agreement, become two of Polyplus’ growing number of sub-licensees who have acquired rights to use of PEI-mediated transfection applications for research purposes. The license provides the NIAID and the NCI with freedom to use this globally recognized high performance technology, from Polyplus-transfection, in its research to produce transfected cells, proteins, viruses and antibodies.
Polyplus-transfection is the worldwide, exclusive licensee to PEI for transfection applications. Transfection with PEI has the advantages of ease of use, high transfection efficiency and excellent viability in the lines of mammalian cells most frequently chosen by scientists working in protein, virus and antibody production.
“Signing this license agreement between Polyplus and the NIAID and the NCI, two major US research institutes, keeps our technology at the forefront of the battle to understand, treat and prevent cancer, as well as other infectious, immunologic and allergic diseases,” said Mark Bloomfield, CEO of Polyplus-transfection. “PEI-mediated transfection has become a core tool for all researchers working in these fields. The execution of this agreement with the NIH is another demonstration of the strength and significant value of Polyplus’ specific intellectual property rights in PEI-mediated nucleic acid delivery for research purposes.”
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
NovogeneAIT Singapore and the Genome Institute of Singapore forge Public-Private Partnership - Establishing whole genome sequencing centre in Singapore
One Year of GATTEX(TM) Therapy Safely Reduces Parenteral Nutrition Dependence for Patients with Short Bowel Syndrome - Results Presented at American College of Gastroenterology Annual Meeting Show Majority of Responders Continued to Benefit from GATTEX in Phase 3-Extension Study
Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million - "This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future"
Thermo Fisher Scientific Forms Consortium to Drive Immunotherapy Research Across Europe
Risk of lead poisoning from urban gardening is low, new study finds
World first: Launch of Quebec registry for users of medical cannabis - MUHC researcher heads one of the largest studies ever conducted on medical cannabis
Implant-based cancer vaccine is first to eliminate tumors in mice - New approach reprograms the mammalian immune system to attack tumors body-wide
Study IDs link between sugar signaling and regulation of oil production in plants
It all adds up: Study finds forever chemicals are more toxic as mixtures - Research also finds that PFOA and PFOS are major contributors to toxicity
Affibody to publish data on therapeutic effects of Affibody molecules in a cancer model
‘Seaweed drug’ helps fight off infection - Alginates found in seaweed can combat multi-drug resistant infections
